drugset / Trial / NCT03224585

Treatment of Acute Pericarditis With Anakinra

NCT03224585

Phase 2 Terminated 5 enrolled Virginia Commonwealth University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to determine the safety and efficacy of anakinra for the treatment of acute pericarditis when initiated within 6 hours of diagnosis and continued for 3 or 7 days. 1. to determine the efficacy of anakinra with respect to chest pain resolution 2. to determine the safety of anakinra with respect to adverse drug events

Timeline

Start
2018-05-11
Primary completion
2020-02-01
Completion
2020-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications